论文部分内容阅读
20世纪90年代中期以来,已有许多临床试验证实他汀类药物可通过降低胆固醇来减少死亡和心血管事件。瑞舒伐他汀是他汀类药物家族的新成员。本研究旨在进一步探讨瑞舒伐他汀的临床应用价值。
Since the mid-1990s, many clinical trials have confirmed that statins reduce death and cardiovascular events by lowering cholesterol. Rosuvastatin is a new member of the statin family. The purpose of this study is to further investigate the clinical value of rosuvastatin.